Free Trial

Marker Therapeutics (MRKR) Competitors

Marker Therapeutics logo
$1.04 +0.01 (+0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.03 -0.01 (-0.48%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MRKR vs. BCAB, ZIVO, ATNM, AADI, INMB, IPSC, ADAP, VNRX, ESLA, and KPTI

Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include BioAtla (BCAB), ZIVO Bioscience (ZIVO), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), INmune Bio (INMB), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), VolitionRx (VNRX), Estrella Immunopharma (ESLA), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry.

Marker Therapeutics vs. Its Competitors

BioAtla (NASDAQ:BCAB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Marker Therapeutics has a consensus target price of $10.25, indicating a potential upside of 885.58%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than BioAtla.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Marker Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, BioAtla had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for BioAtla and 0 mentions for Marker Therapeutics. BioAtla's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company Overall Sentiment
BioAtla Neutral
Marker Therapeutics Neutral

Marker Therapeutics has lower revenue, but higher earnings than BioAtla. Marker Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtla$11M3.68-$69.78M-$1.10-0.63
Marker Therapeutics$6.59M2.04-$10.73M-$1.37-0.76

BioAtla has a net margin of 0.00% compared to Marker Therapeutics' net margin of -271.12%. Marker Therapeutics' return on equity of -114.59% beat BioAtla's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAtlaN/A -1,177.18% -137.51%
Marker Therapeutics -271.12%-114.59%-90.31%

BioAtla has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

77.2% of BioAtla shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 11.2% of BioAtla shares are held by insiders. Comparatively, 7.8% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BioAtla and Marker Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

MetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$13.46M$2.62B$6.11B$10.62B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-0.7623.5929.2227.30
Price / Sales2.04587.20491.48184.03
Price / CashN/A27.2425.8230.35
Price / Book0.605.4112.476.65
Net Income-$10.73M$33.06M$3.32B$276.14M
7 Day Performance-1.89%1.33%1.87%0.01%
1 Month Performance9.47%10.15%8.40%3.60%
1 Year Performance-71.89%-2.20%63.49%32.76%

Marker Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRKR
Marker Therapeutics
3.7239 of 5 stars
$1.04
+1.0%
$10.25
+885.6%
-70.7%$13.46M$6.59M-0.7660
BCAB
BioAtla
0.4972 of 5 stars
$0.91
+4.9%
N/A-68.4%$50.94M$11M-0.8360News Coverage
Gap Up
ZIVO
ZIVO Bioscience
0.5951 of 5 stars
$13.20
+1.5%
N/A-32.5%$50.85M$15.85K-2.7010Gap Up
ATNM
Actinium Pharmaceuticals
2.1038 of 5 stars
$1.61
+8.1%
$4.50
+179.5%
-16.5%$50.23MN/A-1.1630
AADI
Aadi Bioscience
N/A$2.02
-6.9%
N/A+4.7%$49.89M$25.07M-0.8940
INMB
INmune Bio
1.7809 of 5 stars
$1.83
-1.6%
$18.50
+910.9%
-62.4%$49.45M$10K-0.7410
IPSC
Century Therapeutics
2.5816 of 5 stars
$0.55
-3.3%
$3.75
+581.9%
-64.3%$49.13M$6.59M-1.90170News Coverage
Analyst Downgrade
ADAP
Adaptimmune Therapeutics
1.9378 of 5 stars
$0.18
-2.6%
$1.35
+650.5%
-93.0%$49.01M$178.03M-0.28490News Coverage
Gap Down
VNRX
VolitionRx
2.8948 of 5 stars
$0.45
-2.5%
$3.50
+673.1%
-38.9%$48.71M$1.32M-1.2680Positive News
Gap Up
High Trading Volume
ESLA
Estrella Immunopharma
2.8926 of 5 stars
$1.50
+16.3%
$16.00
+966.7%
+128.7%$47.81MN/A-5.77N/APositive News
Short Interest ↓
High Trading Volume
KPTI
Karyopharm Therapeutics
4.2823 of 5 stars
$5.62
+2.2%
$18.20
+223.8%
-50.4%$47.69M$145.24M-0.39380

Related Companies and Tools


This page (NASDAQ:MRKR) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners